Related Experiment Video
Updated: Jun 1, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
[Progress and perspectives in treatment of chronic hepatitis B]
Masahito Minami1, Takeshi Okanoue
1Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine.
Abstract:
In Japan there are four approved anti-hepatitis B virus drugs available. Interferon has both antiviral and immune-modulatory effects. When it is effective, the durable treatment responses can be obtained. Three nucleoside and nucleotide analogues, lamivudine, adefovir, and entecavir, are potent oral inhibitors of HBV replication and well-tolerable. Though these drugs have greatly improved clinical course of chronic hepatitis B, it is still difficult to eradicate HBV from carriers. Several trials of combination of nucleoside analogues and interferon have been reported and some showed improved treatment responses. Further studies are needed to explore the best way to combine several drugs or to discover new anti-HBV drugs.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Chronic Pancreatitis II: Collaborative Care
Assessment:
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Chronic Pancreatitis I: Introduction
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...

